MMIT Reality Check on Breast Cancer HR+/HER2- (Sep 2020)

According to our recent payer coverage analysis for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for breast cancer (HR+/HER2-) treatments shows that under the pharmacy benefit, about 52% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: In December 2019, the FDA approved Teva Pharmaceuticals USA, Inc.’s and Endo International plc unit Par Pharmaceuticals’ everolimus for the treatment of advanced hormone receptor-positive, HER2- negative breast cancer in postmenopausal women, among other indications. The tablets are the first generics of Novartis International AG’s Afinitor (everolimus).

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

May 13

MMIT Reality Check on Narcolepsy

Read More
nurse-doing-blood-test
May 6

MMIT Reality Check on Hemophilia B (Factor IX)

Read More
April 29

MMIT Reality Check on Anemia Due to Chronic Kidney Disease

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today